Biliary tract cancers include cancers of the gallbladder, ampulla of Vater, and bile ducts. About 3% of gastrointestinal malignancies are caused by this uncommon cancer. It is categorized as gallbladder and ampullary malignancies, as well as intrahepatic, helar, and extrahepatic cholangiocarcinomas. Chronic inflammation, primary sclerosing cholangitis, and liver fluke infections are risk factors. Biliary tract cancers is frequently discovered at advanced stages and is becoming more common worldwide in some areas. The biliary tract cancers pipeline analysis by the publisher focuses on various treatment options for this disease.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to biliary tract cancers.
The kind and stage of biliary tract carcinoma determines how it is treated. The sole treatment for localized BTC is surgery, though liver transplantation may be an option in certain circumstances. Chemotherapy, usually gemcitabine-cisplatin, is used to treat advanced BTC. Immunotherapy, such as durvalumab or pembrolizumab, is frequently used in conjunction with chemotherapy. For mutations, targeted treatments such as FGFR2 and IDH1 inhibitors are employed. Stent placement, photodynamic therapy, and locoregional treatments are examples of palliative strategies.
In the biliary tract cancers pipeline, most candidates are in Phase II with 60% of the projects, followed by 20% in Phase I and 20% in Phase III demonstrating a broad spectrum of development stages and diverse progress toward potential treatments.
Capsid assembly modulators (CAMs) are emerging as promising agents in the biliary tract cancers pipeline. For example, HAP18, a small molecule assembly agonist, disrupts the HBV core protein dimer’s hydrogen bonding while stabilizing capsids. This dual action results in empty, defective capsids and impedes viral genome release, reducing the formation of new infectious particles.
This product will be delivered within 3-5 business days.
Report Coverage
The Biliary Tract Cancers Pipeline Analysis Report by the publisher gives comprehensive insights into biliary tract cancers therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for biliary tract cancers. The biliary tract cancers report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The biliary tract cancers pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with biliary tract cancers treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to biliary tract cancers.
Biliary Tract Cancers Pipeline Outlook
Biliary tract cancers are an uncommon class of cancers that involve the gallbladder and bile ducts. It includes malignancies of the gallbladder, ampulla of Vater, intrahepatic, and extrahepatic regions.The kind and stage of biliary tract carcinoma determines how it is treated. The sole treatment for localized BTC is surgery, though liver transplantation may be an option in certain circumstances. Chemotherapy, usually gemcitabine-cisplatin, is used to treat advanced BTC. Immunotherapy, such as durvalumab or pembrolizumab, is frequently used in conjunction with chemotherapy. For mutations, targeted treatments such as FGFR2 and IDH1 inhibitors are employed. Stent placement, photodynamic therapy, and locoregional treatments are examples of palliative strategies.
Biliary Tract Cancers Epidemiology
Biliary tract cancers are uncommon and varies greatly by region. Each year, about 8,000 cases of intrahepatic and extrahepatic bile duct malignancies are detected in the United States. Southeast Asia has a greater prevalence of liver fluke infections worldwide. Older people are impacted most often.Biliary Tract Cancers - Pipeline Therapeutic Assessment
This section of the report covers the analysis of biliary tract cancers drug candidates based on several segmentations, including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Monoclonal antibody
- Peptides
- Small molecule
By Route of Administration
- Oral
- Parenteral
- Others
Biliary Tract Cancers - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total biliary tract cancers clinical trials.In the biliary tract cancers pipeline, most candidates are in Phase II with 60% of the projects, followed by 20% in Phase I and 20% in Phase III demonstrating a broad spectrum of development stages and diverse progress toward potential treatments.
Biliary Tract Cancers - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the biliary tract cancers pipeline analysis include Monoclonal antibody, Peptides and Small molecule. The biliary tract cancers report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for biliary tract cancers.Capsid assembly modulators (CAMs) are emerging as promising agents in the biliary tract cancers pipeline. For example, HAP18, a small molecule assembly agonist, disrupts the HBV core protein dimer’s hydrogen bonding while stabilizing capsids. This dual action results in empty, defective capsids and impedes viral genome release, reducing the formation of new infectious particles.
Biliary Tract Cancers Clinical Trials - Key Players
The report for the biliary tract cancers pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in biliary tract cancers clinical trials:- Eli Lilly and Company
- Merck Sharp & Dohme LLC
- Compass Therapeutics
- Boehringer Ingelheim
- Jazz Pharmaceuticals
- AstraZeneca
- 3D Medicines (Sichuan) Co., Ltd.
- RemeGen Co., Ltd.
- Fujifilm Pharmaceuticals U.S.A., Inc.
Biliary Tract Cancers Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for biliary tract cancers. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of biliary tract cancers drug candidates.Drug: Pembrolizumab
Pembrolizumab, developed by Merck Sharp & Dohme LLC, is in Phase 3 of a clinical trial for treating biliary tract cancer. The trial evaluates its safety and efficacy, particularly in combination with chemotherapy, aiming to improve progression-free and overall survival. Pembrolizumab is an anti-PD-1 monoclonal antibody that boosts the immune system's ability to detect and fight cancer cells.Drug: Ramucirumab
Eli Lilly and Company's Ramucirumab is undergoing Phase 2 of a clinical trial to treat biliary tract cancer. The goal of the experiment is to increase overall survival and progression-free survival by assessing its safety and effectiveness, especially when combined with chemotherapy. Ramucirumab is a monoclonal antibody that inhibits VEGFR-2, preventing the development of blood vessels that supply tumors with nutrients.Key Questions Answered in the Biliary Tract Cancers Pipeline Analysis Report
- Which companies/institutions are leading the biliary tract cancers drug development?
- What is the efficacy and safety profile of biliary tract cancers pipeline drugs?
- Which company is leading the biliary tract cancers pipeline development activities?
- What is the current biliary tract cancers commercial assessment?
- What are the opportunities and challenges present in the biliary tract cancers pipeline landscape?
- Which company is conducting major trials for biliary tract cancers drugs?
- Which companies/institutions are involved in biliary tract cancers collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in biliary tract cancers?
Reasons To Buy This Report
The Biliary Tract Cancers Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for biliary tract cancers. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into biliary tract cancers collaborations, regulatory environments, and potential growth opportunities.This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Biliary Tract Cancers
4 Patient Profile: Biliary Tract Cancers
5 Biliary Tract Cancers: Epidemiology Snapshot
6 Biliary Tract Cancers: Market Dynamics
7 Biliary Tract Cancers: Key Facts Covered
8 Biliary Tract Cancers, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Biliary Tract Cancers Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Biliary Tract Cancers Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Biliary Tract Cancers Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Biliary Tract Cancers, Key Drug Pipeline Companies
